SNCB and Parkinson disease: The presence of β-synuclein could, therefore, contribute to the suppression of both the initiation of aggregation and the proliferation of aggregates in vivo and hence acts as a natural inhibitor of both the onset and spreading of neurodegeneration in disorders such as Parkinson’s disease.